NCT01922271 - Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter

Enrollment

152

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

NVA237

NVA237 44 µg inhalation capsules once daily, delivered via single-dose dry-powder inhaler (SDDPI)

DRUG

Tiotropium

Tiotropium 18 μg once daily delivered via HandiHaler® device.

DRUG

Placebo to NVA237

Placebo to NVA237 once daily, delivered via single-dose dry-powder inhaler (SDDPI).

DRUG

Placebo to tiotropium

Placebo to tiotropium once daily delivered via HandiHaler® device

DRUG

Salbutamol

Used as resuce medication

Trial Locations (14)

12043

Novartis Investigative Site, Berlin

12203

Novartis Investigative Site, Berlin

12687

Novartis Investigative Site, Berlin

13086

Novartis Investigative Site, Berlin

15562

Novartis Investigative Site, Rüdersdorf

20354

Novartis Investigative Site, Hamburg

22947

Novartis Investigative Site, Großhansdorf

23552

Novartis Investigative Site, Lübeck

34121

Novartis Investigative Site, Kassel

45879

Novartis Investigative Site, Gelsenkirchen

51643

Novartis Investigative Site, Gummersbach

60596

Novartis Investigative Site, Frankfurt

96515

Novartis Investigative Site, Sonneberg

04207

Novartis Investigative Site, Leipzig